Stay updated with breaking news from Tim Demuth. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
16.04.2023 - EQS-News: MorphoSys AG / Key word(s): Miscellaneous MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi (tafasitamab-cxix) 16.04.2023 / ...
- Results from the Phase 2 L-MIND study were highlighted as a late-breaking oral presentation at the American Association for Cancer Research Annual Meeting 2023 ... | June 19, 2023
Morphosys is making faster progress than expected with research on its hopeful drug Pelabresib. Key results from the pivotal Phase 3 trial of its drug for the rare bone marrow cancer myelofibrosis... | April 5, 2023
EQS-News: MorphoSys AG / Key word: Miscellaneous MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023... | April 4, 2023
EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023 04.04.2023 / 22:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germa...